BioCentury
ARTICLE | Politics & Policy

ODAC to discuss accelerated approval requirements

January 7, 2011 1:37 AM UTC

FDA's Oncologic Drugs Advisory Committee will meet on Feb. 8 to discuss ways to improve postmarketing trials required to confirm the benefit of drugs that received accelerated approval. The committee will review the status of postmarketing requirements for six drugs that received accelerated approval. ...